Stocks · News reference
Haemonetics shares are trading higher after BTIG maintained its Buy rating on the stock and raised its price target from $110 to $130.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Haemonetics Stock Hits 52-Week High - Here's Why
Haemonetics stock hits a new 52-week high after CSL Plasma outlines a sweeping rollout of its technology across existing U.S. centers.
Helen Of Troy Posts Upbeat Q2 Earnings, Joins Pacira Biosciences, Wolfspeed And Other Big Stocks Moving Higher On Thursday
U.S. stocks fell, while Helen of Troy jumped 15.5% on strong earnings and raised guidance. Pacira soared 44.1% on Viatris acquisition news.